Clinical Evaluation of Umifenovir as a Potential Antiviral Therapy for COVID-19: A Multi-center, Randomized, Controlled Clinical Trial
While umifenovir exhibited some immunological benefits in COVID-19 patients, it did not significantly improve broader patient-important outcomes compared to standard care. Therefore, its routine use in clinical practice for COVID-19 treatment is currently not justified, highlighting the need for further research to explore alternative therapeutic strategies.
Authors
- Behnam Bayatani
- Bita Shahrami (ORCID: https://orcid.org/0000-0002-5383-782X)
- Yunes Panahi (ORCID: https://orcid.org/0000-0002-2504-8356)
- Parisa Kianpour (ORCID: https://orcid.org/0000-0002-0582-6560)
- Azar Hadadi (ORCID: https://orcid.org/0000-0001-5080-6887)
- Farhad Najmeddin (ORCID: https://orcid.org/0000-0002-1595-0127)
- Mahnaz Montazeri (ORCID: https://orcid.org/0000-0002-5914-4741)
- Reza Mourtami
- Sajad Sahab Negah (ORCID: https://orcid.org/0000-0002-2242-9794)
- Morteza Izadi
- Negin Bagher
- Ali Qazivini
- Mojtaba Mojtaheszadeh (ORCID: https://orcid.org/0000-0003-2160-9301)
Institutions
- Baqiyatallah University of Medical Sciences (IR)
- Mashhad University of Medical Sciences (IR)
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- Oman Medical Journal
- Published
- 2024-12-10
- DOI
- https://doi.org/10.5001/omj.2025.51
- Citations
- 1
- Primary Topic
- Infectious Encephalopathies and Encephalitis
- Type
- article
- Field-Weighted Citation Impact
- 0.39